Effect of D-glucitol-hexanicotinate on platelet aggregability in patients with coronary heart disease.
D-glucitol-hexanicotinate (sorbinicate) was administered at a daily dose of 1.6 mg to 16 male patients who had survived myocardial infarction. Platelet aggregation induced by collagen (5 micrograms/ml), by ADP (2, 1.2, 0.8, and 0.4 X 10(-6)M), and by epinephrine (1 and 0.5 X 10(-6)M) was significantly decreased after 3 months of therapy. In a group of 13 comparable patients, who did not receive sorbinicate, platelet aggregation induced by ADP (1.2, 0.8, and 0.4 X 10(-6)M) and by epinephrine (1 X 10(-5)M and 1 X 10(-6)M) was significantly increased 3 months after entry into the study. Sorbinicate has effective lipid-lowering activity; the combination of hypolipidemic and anti-aggregating properties may prove important in primary and secondary prevention of atherosclerotic disease.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D003327:Coronary Disease / Q000097:blood*; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood; D009539:Nicotinic Acids / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D013012:Sorbitol / Q000031:analogs & derivatives* / Q000494:pharmacology
D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; C015238:glucitol hexanicotinate; D013012:Sorbitol; D000244:Adenosine Diphosphate; D004837:Epinephrine